Ic therapy is a treatment Bleomycin 9041-93-4option in the guidelines on the basis of several fi ndings from a phase III study involved who was undergoing chemotherapy with docetaxel and prednisone associated with improved survival rate was recommended response to pain and quality of life T with mitoxantrone plus prednisone compared, and the regime is now a standard fi rst-line treatment option for this patient group. The r The second-line chemotherapy is less clear. Docetaxel is a degree of effectiveness of the M Men who responded to docetaxel fi rst line shown, although there is no level 1 evidence to support it. In addition, the receiver singer has the other chemotherapeutic agents in this context Descr Nkt. As such, the goal of the treatment alleviating symptoms of analgesics, radiation therapy and bisphosphonates’m Ren, with the choice of treatment h Frequently matched to each patient. Although some studies have also shown that bisphosphonates nnern the risk of complications from bone M MCRPC with bone metastases and reduce, their effectiveness remains controversial in this context. Taken together, these data indicate that Behandlungsm opportunities In Gro Britain for M Men with mCRPC were limited, and there is a lack of a unified approach, especially in the second row. Treatment decisions are often based on a patient S response to previous treatment, the number and duration of prior therapy, and the rate of progression. This lack of a standard approach will continue to be used by different definitions of terminology and definitions are still in clinical practice to describe this group of patients difficult. However, with some promising new agents with activity t is the landscape treatment of prostate cancer in Gro Probably Britain Ver Undergo significant changes cant. With its cutting-edge therapies in advanced clinical development, it is likely that treatment options are currently available in Gro Britain for M Men with mCPRC k Nnte bient t be a thing of the past, descriptions Nkt. However, as we face the reality T of an infl UX several new treatment options may be essential to identify the most important factors in our decision making process and an optimal, standardized approach for the treatment of so that new therapies can be mCRPC and in our as a treatment algorithm clinical practice. In this context, we conducted a survey of UK oncologists on current management strategies for patients with advanced prostate cancer to be assessed to identify the most important factors in their decision making and to better understand the R resembled the m emerging therapies in Gro UK clinical practice future. Materials and Methods A semi-structured questionnaire with 16 questions was developed by the British Urological Oncology members of society that have been completed, and again during the error w A closed meeting of the members of VER Published company. The questionnaire was developed by the authors and has been developed to the current RST-Fi and second-line treatment in Great uss Britain evaluate strategies for patients with advanced CRPC and identify Fluorouracil 51-21-8 important factors influences the thinking of the process of clinical decision making by the attending physician . The survey found au Addition designed so that opinions about the m Resembled effects of the evolving state of the art therapy on the clinical management of patients with CRPC in the n Chsten 5 years to advertise.